Clarius Group LLC Has $130,000 Holdings in Athira Pharma, Inc. (NASDAQ:ATHA)

Clarius Group LLC boosted its holdings in shares of Athira Pharma, Inc. (NASDAQ:ATHA) by 35.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 53,551 shares of the company’s stock after acquiring an additional 14,124 shares during the quarter. Clarius Group LLC’s holdings in Athira Pharma were worth $130,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. American Century Companies Inc. acquired a new stake in Athira Pharma during the 3rd quarter worth about $31,000. Jacobs Levy Equity Management Inc. boosted its position in Athira Pharma by 49.3% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 299,661 shares of the company’s stock worth $605,000 after acquiring an additional 98,912 shares during the period. Laird Norton Trust Company LLC boosted its position in Athira Pharma by 21.3% during the 3rd quarter. Laird Norton Trust Company LLC now owns 178,709 shares of the company’s stock worth $361,000 after acquiring an additional 31,400 shares during the period. Nan Fung Group Holdings Ltd boosted its position in Athira Pharma by 1,429.4% during the 3rd quarter. Nan Fung Group Holdings Ltd now owns 180,000 shares of the company’s stock worth $364,000 after acquiring an additional 168,231 shares during the period. Finally, UBS Group AG boosted its position in Athira Pharma by 251.6% during the 3rd quarter. UBS Group AG now owns 99,502 shares of the company’s stock worth $201,000 after acquiring an additional 71,206 shares during the period. 57.12% of the stock is currently owned by institutional investors and hedge funds.

Athira Pharma Trading Down 15.6 %

Shares of NASDAQ ATHA opened at $2.06 on Tuesday. The firm has a market capitalization of $78.96 million, a PE ratio of -0.67 and a beta of 2.78. Athira Pharma, Inc. has a one year low of $1.33 and a one year high of $4.30. The business has a 50-day moving average price of $3.08 and a two-hundred day moving average price of $2.46.

Athira Pharma (NASDAQ:ATHA) last announced its quarterly earnings results on Thursday, February 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.96) by $0.25. Research analysts anticipate that Athira Pharma, Inc. will post -2.86 EPS for the current year.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is ATH-1017 Fosgonimeton, a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.